Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 10;16(7):988.
doi: 10.3390/ph16070988.

The Effects of Perilla frutescens Extracts on IgA Nephropathy: A Systematic Review and Meta-Analysis

Gigi Adam  1   2 , Ana-Maria Adam  3 , Silvia Robu  3 , Valeriu Harabor  3 , Anamaria Harabor  3 , Aurel Nechita  3 , Denisa Batir Marin  1 , Ionela-Daniela Morariu  1 , Oana Cioanca  1 , Ingrid-Andrada Vasilache  4 , Monica Hancianu  1
Affiliations
Review

The Effects of Perilla frutescens Extracts on IgA Nephropathy: A Systematic Review and Meta-Analysis

Gigi Adam et al. Pharmaceuticals (Basel). .

Abstract

(1) Background: Chronic renal disorders (CRD) are associated with significant comorbidities and necessitate complex therapeutic management. As time passed, Perilla frutescens (PF) became a promising therapeutic option for CRD. The aim of this systematic review and meta-analysis was to outline the therapeutic effects of PF extracts on various models of immunoglobulin a (IgA) nephropathy; (2) Methods: Medline, Embase, and Cochrane databases were used to find relevant studies. All prospective interventional studies that evaluated the effect of PF extract versus placebo on rat models of chronic renal disorders were assessed according to the international guidelines; (3) Results: Our search yielded 23 unique records, out of which only five were included in the analysis. Our results showed that administration of PF extracts led to a statistically significant reduction in proteinuria and PCNA levels in rats that received high doses of the extract as well as in the PCNA level and DNA synthesis in rats that received low doses of the extract. The evaluated outcomes benefited from a low degree of heterogeneity; (4) Conclusions: Some of the evaluated outcomes were significantly reduced by both high and low doses of extracts from Perilla frutescens. Further studies are needed to determine the exact effect over IgA nephropathy in human subjects.

Keywords: IgA nephropathy; Perilla frutescens; extract; mesangioproliferative glomerulonephritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of search and selection of studies.
Figure 2
Figure 2
Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on proteinuria [32,33,34,35].
Figure 3
Figure 3
Forrest plot for overall effect size of high-dose Perilla frutescens versus placebo on proteinuria [32,34].
Figure 4
Figure 4
Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on serum levels of immunoglobulin A [31,34,35].
Figure 5
Figure 5
Forrest plot for overall effect size of high-dose Perilla frutescens versus placebo on serum levels of immunoglobulin A [31,34].
Figure 6
Figure 6
Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on the positivity for proliferating cell nuclear antigen (PCNA) [32,33].
Figure 7
Figure 7
Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on the DNA synthesis [31,32].
Figure 8
Figure 8
Forrest plot for overall effect size of high-dose Perilla frutescens versus placebo on the DNA synthesis [31,32].
Figure 9
Figure 9
Funnel plot for publication bias.
See this image and copyright information in PMC

References

    1. De Nicola L., Zoccali C. Chronic kidney disease prevalence in the general population: Heterogeneity and concerns. Nephrol. Dial. Transplant. 2016;31:331–335. doi: 10.1093/ndt/gfv427. - DOI - PubMed
    1. Ene-Iordache B., Perico N., Bikbov B., Carminati S., Remuzzi A., Perna A., Islam N., Bravo R.F., Aleckovic-Halilovic M., Zou H., et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study. Lancet Glob. Health. 2016;4:e307–e319. doi: 10.1016/S2214-109X(16)00071-1. - DOI - PubMed
    1. De Nicola L., Donfrancesco C., Minutolo R., Lo Noce C., Palmieri L., De Curtis A., Iacoviello L., Zoccali C., Gesualdo L., Conte G., et al. Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: Results of the 2008-12 National Health Examination Survey. Nephrol. Dial. Transplant. 2015;30:806–814. doi: 10.1093/ndt/gfu383. - DOI - PubMed
    1. Ebert N., Jakob O., Gaedeke J., van der Giet M., Kuhlmann M.K., Martus P., Mielke N., Schuchardt M., Tölle M., Wenning V., et al. Prevalence of reduced kidney function and albuminuria in older adults: The Berlin Initiative Study. Nephrol. Dial. Transplant. 2017;32:997–1005. doi: 10.1093/ndt/gfw079. - DOI - PubMed
    1. Brück K., Stel V.S., Gambaro G., Hallan S., Völzke H., Ärnlöv J., Kastarinen M., Guessous I., Vinhas J., Stengel B., et al. CKD Prevalence Varies across the European General Population. J. Am. Soc. Nephrol. 2016;27:2135–2147. doi: 10.1681/ASN.2015050542. - DOI - PMC - PubMed